Antagonists of LRP6 regulate PTH-induced cAMP generation

Annals of the New York Academy of Sciences

Volumn 1237, Issue 1, 2011, Pages 39-46

  Shi, Chenhui ^a   Li, Jun ^a   Wang, Weishan ^a   Cao, Weiwei ^a   Cao, Xu ^b   Wan, Mei ^b  

^a SHIHEZI UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CAMP production; DKK1; LRP6; PTH; Sclerostin

Indexed keywords

CYCLIC AMP; DICKKOPF 1 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PARATHYROID HORMONE; SCLEROSTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; OSTEOCYTE; POSITIVE FEEDBACK; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

MUS;

EID: 81255176589     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06226.x     Document Type: Article

References (54)

1. Tamai, K. et al 2000. LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530-535.
2. Pinson, K.I., J. Brennan, S. Monkley, et al 2000. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407: 535-538.
3. Mao, J. et al 2001. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7: 801-809.
4. Tamai, K. et al 2004. A mechanism for Wnt coreceptor activation. Mol. Cell 13: 149-156.
5. Semenov, M.V. et al 2001. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 11: 951-961.
6. Mao, B. et al 2001. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411: 321-325.
7. Bafico, A., G. Liu, A. Yaniv, et al 2001. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 3: 683-686.
8. Semenov, M., K. Tamai & X. He 2005. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280: 26770-26775.
9. Semenov, M.V. & X. He 2006. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281: 38276-38284.
10. Li, X. et al 2005. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280: 19883-19887.
11. Ellies, D.L. et al 2006. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21: 1738-1749.
12. Mason, J.J. & B.O. Williams 2010. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J. Osteoporos. 2010: pii: 460120.
13. Balemans, W. et al 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10: 537-543.
14. Loots, G.G. et al 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15: 928-935.
15. Keller, H. & M. Kneissel 2005. SOST is a target gene for PTH in bone. Bone 37: 148-158.
16. Bellido, T. et al 2005. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583.
17. Leupin, O. et al 2007. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22: 1957-1967.
18. Murray, T.M., L.G. Rao, P. Divieti & F.R. Bringhurst 2005. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr. Rev. 26: 78-113.
19. Jilka, R.L. 2007. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446.
20. Potts, J.T. & T.J. Gardella 2007. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann. N. Y. Acad. Sci. 1117: 196-208.
21. bou-Samra, A.B. et al 1992. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. USA 89: 2732-2736.
22. Juppner, H. et al 1991. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254: 1024-1026.
23. Yamaguchi, D.T., T.J. Hahn, A. Iida-Klein, et al 1987. Parathyroid hormone-activated calcium channels in an osteoblast-like clonal osteosarcoma cell line. cAMP-dependent and cAMP-independent calcium channels. J. Biol. Chem. 262: 7711-7718.
24. Civitelli, R., I.R. Reid, S. Westbrook, et al 1988. PTH elevates inositol polyphosphates and diacylglycerol in a rat osteoblast-like cell line. Am. J. Physiol. 255: E660-E667.
25. Donahue, H.J., M.J. Fryer, E.F. Eriksen & H. Heath 1988. III Differential effects of parathyroid hormone and its analogues on cytosolic calcium ion and cAMP levels in cultured rat osteoblast-like cells. J. Biol. Chem. 263: 13522-13527.
26. Babich, M., K.L. King & R.A.G Nissenson 1989. Protein-dependent activation of a phosphoinositide-specific phospholipase C in UMR-106 osteosarcoma cell membranes. J. Bone Miner. Res. 4: 549-556.
27. bou-Samra, A.B., H. Jueppner, D. Westerberg, et al 1989. Parathyroid hormone causes translocation of protein kinase-C from cytosol to membranes in rat osteosarcoma cells. Endocrinology 124: 1107-1113.
28. Wan, M. et al 2008. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 22: 2968-2979.
29. Wan, M. et al 2011. LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Galpha(s). Sci. Signal. 4: ra15.
30. Gallo-Payet, N. & M.D. Payet 1989. Excitation-secretion coupling: involvement of potassium channels in ACTH-stimulated rat adrenocortical cells. J. Endocrinol. 120: 409-421.
31. Kilianova, Z., N. Basora, P. Kilian, et al 2006. Human melanocortin receptor 2 expression and functionality: effects of protein kinase A and protein kinase C on desensitization and internalization. Endocrinology 147: 2325-2337.
32. Violin, J. D. et al 2008. Beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics. J. Biol. Chem. 283: 2949-2961.
33. DiPilato, L.M. & J. Zhang 2009. The role of membrane microdomains in shaping beta2-adrenergic receptor-mediated cAMP dynamics. Mol. Biosyst. 5: 832-837.
34. DiPilato, L.M., X. Cheng & J. Zhang 2004. Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc. Natl. Acad. Sci. USA 101: 16513-16518.
35. Keller, H. & M. Kneissel 2005. SOST is a target gene for PTH in bone. Bone 37: 148-158.
36. Bellido, T. et al Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583 (2005).
37. Leupin, O. et al Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22: 1957-1967.
38. Keller, H. & M. Kneissel 2005. SOST is a target gene for PTH in bone. Bone 37: 148-158.
39. Bellido, T. et al 2005. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583.
40. Leupin, O. et al 2007. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22: 1957-1967.
41. Winkler, D.G. et al 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22: 6267-6276.
42. Li, X. et al 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23: 860-869.
43. Qin, L., L.J. Raggatt & N.C. Partridge 2004. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab 15: 60-65.
44. Winkler, D.G. et al 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22: 6267-6276.
45. van Bezooijen, R.L. et al 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199: 805-814.
46. Kolpakova, E. & B.R. Olsen 2005. Wnt/beta-catenin-a canonical tale of cell-fate choice in the vertebrate skeleton. Dev. Cell 8: 626-627.
47. Cole, J.A. 1999. Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology 140: 5771-5779.
48. Swarthout, J.T., T.A. Doggett, J.L. Lemker & N.C. Partridge 2001. Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent. J. Biol. Chem. 276: 7586-7592.
49. Hoeppner, L.H., F.J. Secreto & J.J. Westendorf 2009. Wnt signaling as a therapeutic target for bone diseases. Expert. Opin. Ther. Targets. 13: 485-496.
50. Padhi, D., G. Jang, B. Stouch, L. Fang & E. Posvar 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26: 19-26.
51. Rachner, T.D., S. Khosla, & L.C. Hofbauer 2011. Osteoporosis: now and the future. Lancet 377: 1276-1287.
52. Diarra, D. et al 2007. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13: 156-163.
53. Heath, D.J. et al 2009. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 24: 425-436.
54. Fulciniti, M. et al 2009. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379.